BGLC
BioNexus Gene Lab Corp.
There isn't enough reported data to score BGLC yet.
BGLC Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
BGLC's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
BGLC PE Valuation
BGLC has no meaningful PE right now: it lost money over the past year.
BGLC Forward outlook
There aren't enough analyst estimates for BGLC to show an outlook.
BGLC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2022 | -$0.07 | -105% |
| Q2 2022 | -$0.02 | -101% |
| Q1 2022 | $0.07 | -95% |
| Q4 2021 | $0.06 | -96% |
| Q3 2021 | $1.44 | +586% |
| Q2 2021 | $1.44 | +586% |
| Q1 2021 | $1.44 | +1340% |
| Q4 2020 | $1.44 | +$1.44 |
BGLC lost $1.29 per share over the past year, a bigger loss than the year before.
BGLC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $76.2K | -97% |
| Q1 2026 | $22.8K | -99% |
| Q4 2025 | $483.8K | -81% |
| Q3 2025 | $2.5M | -3.3% |
| Q2 2025 | $2.3M | +14% |
| Q1 2025 | $2.1M | -10% |
| Q4 2024 | $2.5M | +11% |
| Q3 2024 | $2.6M | +3% |
BGLC's revenue has slid since its 2020 peak: $76,156 last quarter, down 97% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -371% | -344 points |
| Q1 2026 | -2366% | -2337 points |
| Q4 2025 | -214% | -197 points |
| Q3 2025 | -28% | +23 points |
| Q2 2025 | -27% | -40 points |
| Q1 2025 | -29% | -26 points |
| Q4 2024 | -16% | -28 points |
| Q3 2024 | -51% | +48 points |
BGLC's operating margin was −371% last quarter, down 344 points from the same quarter a year ago, near the bottom of its range since 2019.
BGLC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$422.7K | +$336.6K |
| Q1 2026 | -$148K | +$685.1K |
| Q4 2025 | $960.1K | +$1M |
| Q2 2025 | -$759.4K | -$88.8K |
| Q1 2025 | -$833.1K | -$798.7K |
| Q4 2024 | -$73.8K | +$39.7K |
| Q2 2024 | -$670.5K | -$634.1K |
| Q1 2024 | -$34.4K | +$84K |
BGLC has burned cash in most quarters: −$853,600 over the past year, against −$2M the year before.
BGLC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +35% | +621K shares |
| 3 years | +37% | +647K shares |
| 5 years | +69% | +990K shares |
| Available history | +294% | +1.8M shares |
BGLC has 2M diluted shares, up 35% from a year ago.
BGLC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -3.9x | Net Cash |
| Q2 2022 | -0.9x | Net Cash |
| Q1 2022 | -2.2x | Net Cash |
| Q4 2021 | -1.9x | Net Cash |
| Q3 2021 | -0.7x | Net Cash |
| Q2 2021 | -0.8x | Net Cash |
| Q1 2021 | -1.4x | Net Cash |
| Q4 2020 | -2.0x | Net Cash |
BGLC has more cash than debt.
BGLC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.0 | Oversold |
| Stochastic | 4.3 | Oversold |
BGLC's weekly RSI is 30 (oversold) and its Stochastic is 4 (oversold).
BGLC PE vs Healthcare Sector
| Metric | BGLC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BGLC has no meaningful PE right now: it lost money over the past year.
BGLC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.12 | 19% below |
| 20 week MA | $1.42 | 36% below |
| 50 week MA | $2.19 | 58% below |
| 100 week MA | $3.15 | 71% below |
| 200 week MA | $12.5 | 93% below |
BGLC is in a downtrend: it's below all five of its weekly moving averages, and 93% below its 200-week average.
BGLC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $264.0 | $228.0 | -14% |
| 2022 | $228.0 | $114.0 | -50% |
| 2023 | $114.0 | $5.30 | -95% |
| 2024 | $5.30 | $2.67 | -50% |
| 2025 | $2.67 | $4.14 | +55% |
| 2026 YTD | $4.14 | $0.91 | -78% |
BGLC has finished lower in four of the last five years. It's down 78% so far in 2026.